Industry-Supported Symposium

ITS5: Shifting the Trajectory: Early Intervention Strategies in SLE

Industry Presenter(s)

• 

  Ashira Blazer, MD;MS

  University of Maryland Baltimore
  Baltimore, Maryland, United States

  Disclosure information not submitted.
• 

  Maria Dall'Era, MD

  Director
  UCSF
  Corte Madera, California, United States

  Disclosure information not submitted.

Please note: This session is not eligible for CME Credits through ACR.
This session will not be recorded for on-demand.

This industry-sponsored symposium will highlight how 2025 ACR SLE guidelines support early use of advanced therapies, including biologics, to improve patient outcomes in SLE. This interactive session will explore case studies of patients living with SLE, each with different manifestations of this condition. The session will emphasize the importance of considering early advanced therapies, such as biologics, highlighting the critical factors clinicians should prioritize when making treatment decisions.

Attendees will gain a deeper understanding of the urgent need to minimize organ damage early and the potential role of early advanced therapy initiation in altering the natural course of SLE. The symposium aims to equip clinicians with the knowledge to identify clinical characteristics that support consideration of early advanced therapy intervention and to apply a disease modification framework as a proactive strategy to reduce organ damage and improve patient outcomes. Developed and offered by GSK. Not an official program of the ACR.